Nature Medicine, Published online: 03 February 2025; doi:10.1038/s41591-024-03441-5
The CheckMate-7FL and KEYNOTE-756 trials provide robust evidence for the efficacy of neoadjuvant chemo-immunotherapy in high-risk, early-stage hormone receptor-positive (HER2-negative) breast cancer, and an opportunity to personalize therapy in this population.
